













# GRAPPA Adjacent to EULAR 2023



**Date:** Wednesday May 31, 2023  
**Time:** 11:30-13:30 CET  
**Location:** PIME Theater - Girardi Room  
via Mose Bianchi 94, 20149 Milano

## AGENDA

- |             |   |   |
|-------------|---|---|
| 11:30-11:40 |   | Sign-in, Coffee & Light Refreshments  |
| 11:40-11:55 |    | Welcome & GRAPPA Developments – Oliver FitzGerald, MD, GRAPPA Co-President, Conway Institute, University College Dublin                                     |
| 11:55-12:05 |       | Updates From the GRAPPA Research Committee – Vinod Chandran, MBBS, MD, DM, PhD, FRCPC, University of Toronto and Kurt de Vlam, MD, PhD, KU Leuven           |
| 12:05-12:15 |   | Molecular Characterisation of Axial PsA – Philip Mease, MD, MACR, Swedish Medical Center, Providence St. Joseph Health, University of Washington            |
| 12:15-12:30 |   | IMI Consortium HIPPOCRATES Progress; Focus on the HPOS Study – Steve Pennington BSc, PhD, Conway Institute, University College Dublin and Oliver FitzGerald |
| 12:30-12:40 |   | Educational Outreach – Philip Helliwell, MA, PhD, DM, FRCP, University of Leeds and Philip Mease  |
| 12:40-12:50 |    | Progress with Young-GRAPPA – Fabian Proft, MD, Charité Universitätsmedizin Berlin   |
| 12:50-13:20 |   | That 3VAS/4VAS Scores Are Useful Measures of Disease Activity in Psoriatic Arthritis Debate: Philip Helliwell vs. Alberto Cauli, MD, University of Cagliari |
| 13:20-13:30 |    | Conclusion and Summary – Oliver FitzGerald  |

Thank you to our Corporate Members:

abbvie

ACELYRIN 

AMGEN

Boehringer  
Ingelheim

Bristol Myers Squibb™

janssen  
PHARMACEUTICAL COMPANIES OF  
Johnson & Johnson

Lilly

MoonLake

NOVARTIS

Pfizer

ucb